Agrimonolide exhibits anti-neuroinflammatory potential via TLR4-mediated pathways

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation, driven by microglial and astrocytic activation, significantly contributes to neuronal damage and neurological disorders.
• Current therapeutic options directly targeting neuroinflammation are limited, necessitating the development of novel inhibitors.

Purpose of the Study:

• To identify and characterize novel inhibitors of glia activation from a library of natural compounds.
• To investigate the in vitro and in vivo efficacy of agrimonolide in suppressing neuroinflammation.

Main Methods:

• Screening of 40 compounds to identify glia activation inhibitors.
• In vitro assays using LPS-stimulated BV2 cells and primary astrocytes to measure cytokine expression (IL-1β, IL-6, TNFα).
• In vivo studies in ICR mice to assess glial activation markers (IBA-1, GFAP) and signaling pathway inhibition (NF-κB, MAPK, TLR4).

Main Results:

• Agrimonolide significantly reduced proinflammatory cytokine expression in cellular models.
• Mechanistic studies revealed suppression of NF-κB and MAPK signaling pathways by agrimonolide.
• In vivo, agrimonolide decreased LPS-induced glial activation and inhibited TLR4-mediated signaling.

Conclusions:

• Agrimonolide effectively suppresses neuroinflammation by inhibiting both microglial and astrocytic activation.
• The compound acts through multiple targets, including NF-κB, MAPK, and TLR4 signaling pathways.
• Agrimonolide represents a potential therapeutic candidate for treating neuroinflammation-related diseases.